Hemispheres Level 8 - Excellence in Stroke Care Exam
2025/2026
100% Accurate Answers with Detailed Rationales | Stroke Care Certification | Clinical
Assessment
Overview
This 2025/2026 validated resource contains the complete Hemispheres Level 8 Stroke
Care assessment package with 100% accurate answers and detailed clinical
rationales. Essential for healthcare professionals demonstrating advanced competency in
comprehensive stroke care.
Key Features
✓ 100% Accurate Verified Answers
✓ Evidence-Based Clinical Rationales
✓ Updated 2025/2026 Stroke Care Guidelines
✓ Advanced Clinical Scenarios
✓ Comprehensive Protocol Coverage
Assessment Components
85 Questions with 100% Accurate Answer Rationales
Core Content Areas
Acute Stroke Intervention & Thrombolysis (18 Questions)
Neurological Assessment & Monitoring (16 Questions)
Stroke Unit Protocols & Management (15 Questions)
Rehabilitation & Recovery Planning (14 Questions)
Secondary Prevention Strategies (12 Questions)
Patient & Family Education (10 Questions)
Answer Format
100% accurate answers in bold green with:
Evidence-based protocol explanations
Clinical decision-making pathways
Time-critical intervention rationales
Best practice justifications
🔹
Critical Updates 2025/2026
🔹
NEW - Updated thrombolysis protocols
🔹
UPDATED - Advanced imaging guidelines
REVISED - Neurorehabilitation standards
🔹 MODIFIED - Secondary prevention measures
,Study Materials Include
✓ Clinical pathway references
✓ Assessment scale guides
✓ Intervention protocol charts
✓ Patient management templates
Assessment Features
✓ Timed clinical evaluation
✓ Performance analytics by domain
✓ Customized competency recommendations
✓ Progress validation metrics
Acute Stroke Intervention & Thrombolysis (Questions 1-18)
Question 1: The 2025 AHA/ASA guideline extends the IV alteplase window to what
time frame?
A) 3 hours
B) 4.5 hours from last known well
C) 6 hours
D) 9 hours
Rationale: Extended window applies to select patients with NIHSS <25, no anticoagulant use,
and imaging without extensive infarct. Door-to-needle goal remains ≤60 min. 2025 update
includes perfusion-based selection beyond 4.5 hours.
Question 2: Tenecteplase is preferred over alteplase in which scenario?
A) All ischemic strokes
B) Large vessel occlusion (LVO) with transfer for thrombectomy
C) Hemorrhagic stroke
D) TIA
Rationale: Single bolus 0.25 mg/kg (max 25 mg) allows rapid administration before
inter-facility transfer. EXTEND-IA TNK trials show superior reperfusion. 2025 CSC protocols
mandate tenecteplase for drip-and-ship.
Question 3: Which is an absolute contraindication to IV thrombolysis?
A) BP 180/110
B) Active internal bleeding
C) NIHSS 6
D) Glucose 50 mg/dL
Rationale: Per 2025 AHA guidelines, active bleeding is absolute. BP must be <185/110
pre-bolus; hypoglycemia must be corrected first.
Question 4: The DAWN trial criteria allow thrombectomy up to how many hours?
, A) 6 hours
B) 24 hours with mismatch
C) 12 hours
D) 4.5 hours
Rationale: Clinical-imaging mismatch (NIHSS ≥10, infarct <1/3 MCA) on CTP/MRI. DEFUSE 3
supports 6–16 hours. 2025 extends to basilar occlusion with pc-ASPECTS ≥6.
Question 5: What is the post-thrombolysis BP target?
A) <220/120
B) <180/105 mmHg for 24 hours
C) <160/90
D) Normal range
Rationale: Prevents hemorrhagic transformation. Use IV labetalol, nicardipine. Re-check
q15min. 2025 allows clevidipine for rapid titration.
Question 6: What is the symptom onset to groin puncture goal for thrombectomy?
A) 60 min
B) ≤90 min at CSC
C) 120 min
D) 180 min
Rationale: Picture-to-puncture ≤60 min; puncture-to-recanalization ≤30 min. 2025 metrics
include TICI 2b/3 ≥70% first-pass.
Question 7: When does antiplatelet therapy post-thrombolysis begin?
A) Immediately
B) 24 hours after IV alteplase
C) 12 hours
D) 48 hours
Rationale: Avoids ICH risk. Aspirin 325 mg if no thrombectomy. 2025 allows DAPT if stented.
Question 8: The PRISMS trial showed alteplase benefit in which group?
A) All mild strokes
B) No benefit in NIHSS 0–5
C) Only LVO
D) Hemorrhagic
Rationale: Low-risk mild stroke does not benefit; treat with aspirin. 2025 reserves thrombolysis
for disabling deficits.
Question 9: What is the perfusion imaging mismatch ratio for late window
thrombectomy?
A) >1.2
B) ≥1.8 with core <70 mL
C) ≥1.4
2025/2026
100% Accurate Answers with Detailed Rationales | Stroke Care Certification | Clinical
Assessment
Overview
This 2025/2026 validated resource contains the complete Hemispheres Level 8 Stroke
Care assessment package with 100% accurate answers and detailed clinical
rationales. Essential for healthcare professionals demonstrating advanced competency in
comprehensive stroke care.
Key Features
✓ 100% Accurate Verified Answers
✓ Evidence-Based Clinical Rationales
✓ Updated 2025/2026 Stroke Care Guidelines
✓ Advanced Clinical Scenarios
✓ Comprehensive Protocol Coverage
Assessment Components
85 Questions with 100% Accurate Answer Rationales
Core Content Areas
Acute Stroke Intervention & Thrombolysis (18 Questions)
Neurological Assessment & Monitoring (16 Questions)
Stroke Unit Protocols & Management (15 Questions)
Rehabilitation & Recovery Planning (14 Questions)
Secondary Prevention Strategies (12 Questions)
Patient & Family Education (10 Questions)
Answer Format
100% accurate answers in bold green with:
Evidence-based protocol explanations
Clinical decision-making pathways
Time-critical intervention rationales
Best practice justifications
🔹
Critical Updates 2025/2026
🔹
NEW - Updated thrombolysis protocols
🔹
UPDATED - Advanced imaging guidelines
REVISED - Neurorehabilitation standards
🔹 MODIFIED - Secondary prevention measures
,Study Materials Include
✓ Clinical pathway references
✓ Assessment scale guides
✓ Intervention protocol charts
✓ Patient management templates
Assessment Features
✓ Timed clinical evaluation
✓ Performance analytics by domain
✓ Customized competency recommendations
✓ Progress validation metrics
Acute Stroke Intervention & Thrombolysis (Questions 1-18)
Question 1: The 2025 AHA/ASA guideline extends the IV alteplase window to what
time frame?
A) 3 hours
B) 4.5 hours from last known well
C) 6 hours
D) 9 hours
Rationale: Extended window applies to select patients with NIHSS <25, no anticoagulant use,
and imaging without extensive infarct. Door-to-needle goal remains ≤60 min. 2025 update
includes perfusion-based selection beyond 4.5 hours.
Question 2: Tenecteplase is preferred over alteplase in which scenario?
A) All ischemic strokes
B) Large vessel occlusion (LVO) with transfer for thrombectomy
C) Hemorrhagic stroke
D) TIA
Rationale: Single bolus 0.25 mg/kg (max 25 mg) allows rapid administration before
inter-facility transfer. EXTEND-IA TNK trials show superior reperfusion. 2025 CSC protocols
mandate tenecteplase for drip-and-ship.
Question 3: Which is an absolute contraindication to IV thrombolysis?
A) BP 180/110
B) Active internal bleeding
C) NIHSS 6
D) Glucose 50 mg/dL
Rationale: Per 2025 AHA guidelines, active bleeding is absolute. BP must be <185/110
pre-bolus; hypoglycemia must be corrected first.
Question 4: The DAWN trial criteria allow thrombectomy up to how many hours?
, A) 6 hours
B) 24 hours with mismatch
C) 12 hours
D) 4.5 hours
Rationale: Clinical-imaging mismatch (NIHSS ≥10, infarct <1/3 MCA) on CTP/MRI. DEFUSE 3
supports 6–16 hours. 2025 extends to basilar occlusion with pc-ASPECTS ≥6.
Question 5: What is the post-thrombolysis BP target?
A) <220/120
B) <180/105 mmHg for 24 hours
C) <160/90
D) Normal range
Rationale: Prevents hemorrhagic transformation. Use IV labetalol, nicardipine. Re-check
q15min. 2025 allows clevidipine for rapid titration.
Question 6: What is the symptom onset to groin puncture goal for thrombectomy?
A) 60 min
B) ≤90 min at CSC
C) 120 min
D) 180 min
Rationale: Picture-to-puncture ≤60 min; puncture-to-recanalization ≤30 min. 2025 metrics
include TICI 2b/3 ≥70% first-pass.
Question 7: When does antiplatelet therapy post-thrombolysis begin?
A) Immediately
B) 24 hours after IV alteplase
C) 12 hours
D) 48 hours
Rationale: Avoids ICH risk. Aspirin 325 mg if no thrombectomy. 2025 allows DAPT if stented.
Question 8: The PRISMS trial showed alteplase benefit in which group?
A) All mild strokes
B) No benefit in NIHSS 0–5
C) Only LVO
D) Hemorrhagic
Rationale: Low-risk mild stroke does not benefit; treat with aspirin. 2025 reserves thrombolysis
for disabling deficits.
Question 9: What is the perfusion imaging mismatch ratio for late window
thrombectomy?
A) >1.2
B) ≥1.8 with core <70 mL
C) ≥1.4
